2024年欧洲肿瘤内科学会妇科肿瘤学大会（ESMO Gynaecological Cancers Congress 2024）将于2024年6月20-22日（CEST）在意大利佛罗伦萨盛大举行。近日，大会官方公布了详细日程及研究题目。【肿瘤资讯】从官网获取最新资讯，为您精心整理了已公布的口头报告研究，以飨读者。
优选论文专场
Proffered Paper session
专场时间：2024.06.20 14:45 - 16:15（CEST）
专场主席：Susana Banerjee (London, United Kingdom)；Domenica Lorusso (Milan, Italy)
摘要号：21O
KEYVIBE-005：vibostolimab+帕博利珠单抗复方制剂在晚期宫颈癌中的研究
Coformulated vibostolimab/pembrolizumab in advanced cervical cancer: KEYVIBE-005
讲者: Alexandra Leary (Villejuif, France)
摘要号：22O
转移性宫颈癌中生物标志物与vibostolimab+帕博利珠单抗复方制剂治疗反应的相关性：II期 KEYVIBE-005研究的探索性分析
Association of biomarkers with response to coformulated vibostolimab/pembrolizumab (vibo/pembro) in metastatic cervical cancer (CC): exploratory analysis from the phase 2 KEYVIBE-005 study
讲者: Christophe Le Tourneau (Paris, France)
摘要号： 23O
一项在高危局部晚期宫颈癌患者中评价放化疗±帕博利珠单抗的随机、III期、双盲研究 (KEYNOTE-A18/ENGOT-cx11/GOG-3047)：亚洲人群的结局
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab in Patients with High-Risk, Locally Advanced, Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047): Results for Patients Enrolled in Asia
讲者：向阳 (中国，北京)
摘要号：43O
度伐利尤单抗+卡铂/紫杉醇+贝伐珠单抗，随后给予度伐利尤单抗、贝伐珠单抗和奥拉帕利的维持治疗，用于non-tBRCAm的新诊断晚期卵巢癌：DUO-O研究更新的结果
Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): updated results from DUO-O
讲者: Fabian Trillsch (Munich, Germany)
摘要号：44O
III期 MIRASOL(GOG 3045/ENGOT-ov55) 试验：在接受剂量调整的高叶酸受体α表达的铂耐药卵巢癌 (PROC)患者中比较 Mirvetuximab Soravtansine vs 研究者选择的化疗 (ICC) 的安全性和疗效
Safety and Efficacy Results in Patients Who Received Dose Modifications in the Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) Trial of Mirvetuximab Soravtansine vs Investigator’s Choice Chemotherapy (ICC) in Platinum-Resistant Ovarian Cancer (PROC) with High Folate Receptor-Alpha Expression
讲者: Susana Banerjee (London, United Kingdom)
摘要号：34O
ROCSAN：评价dostarlimab+尼拉帕利 vs尼拉帕利单药治疗至少接受过一线铂类化疗的子宫内膜癌/卵巢癌肉瘤患者的多中心、随机、II/III期研究的初步结果
ROCSAN: A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum-based chemotherapy, preliminary results
讲者：Isabelle L. Ray-Coquard (Lyon, France)
迷你口头报告专场1
Mini Oral session 1
专场时间：2024.06.21 10:20 - 11:50
专场主席：Ana Oaknin (Barcelona, Spain)；Isabelle L. Ray-Coquard (Lyon, France)
摘要号：35MO
AtTEnd/ENGOT-EN7 试验中接受阿替利珠单抗或安慰剂联合卡铂-紫杉醇治疗的晚期或复发性子宫内膜癌患者的质量调整生存分析
Quality-Adjusted Survival in patients with advanced or recurrent endometrial carcinoma treated with atezolizumab in combination with carboplatin-paclitaxel versus carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 Trial
讲者: Maria Pilar Barretina Ginesta (Girona, Spain)
摘要号：36MO
接受阿替利珠单抗或安慰剂联合卡铂-紫杉醇治疗的原发性晚期或复发性子宫内膜癌：AtTEnd/ENGOT-EN7试验中患者报告的结局
Patient-reported outcomes in primary advanced or recurrent endometrial carcinoma treated with atezolizumab or placebo in combination with carboplatin-paclitaxel in the AtTEnd/ENGOT-EN7 Trial
讲者: Yeh Chen Lee (Randwick, Australia)
摘要号：37MO
RUBY试验：Dostarlimab联合化疗治疗原发性晚期或复发性子宫内膜癌 (pA/rEC)：按 MMR状态和分子亚组列出的总生存期
Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: overall survival (OS) by MMR status and molecular subgroups
讲者：Robert L. Coleman (The Woodlands, United States of America)
摘要号：38MO
总体和错配修复正常（MMR/MSS）人群以及组织学和分子亚组中原发性晚期或复发性子宫内膜癌 (pA/rEC) 的无进展生存期：RUBY试验Part 2的结果
Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: results from Part 2 of the RUBY trial
讲者：Mansoor Raza Mirza (Copenhagen, Denmark)
摘要号：39MO
Ⅲ期 ENGOT-En9/LEAP-001研究：仑伐替尼+帕博利珠单抗 vs 化疗作为晚期或复发性子宫内膜癌患者的一线治疗
Phase 3 ENGOT-En9/LEAP-001 Study: Lenvatinib + Pembrolizumab (LEN/PEMBRO) vs Chemotherapy (Chemo) as First-Line (1L) Therapy for Advanced or Recurrent Endometrial Cancer
讲者：Sandro Pignata (Napoli, Italy)
摘要号：40MO
一线度伐利尤单抗+卡铂/紫杉醇，随后度伐利尤单抗±奥拉帕利治疗子宫内膜癌 (DUO-E) ：按MMR状态列出的客观缓解率、缓解持续时间和至治疗中止或死亡的时间 (TDT)
First-line (1L) durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib for endometrial cancer (EC) (DUO-E): Objective response rate (ORR), duration of response (DoR) and time to treatment discontinuation or death (TDT) by mismatch repair (MMR) status
讲者：Els Van Nieuwenhuysen (Leuven, Belgium)
摘要号：82MO
EURACAN 网络内的欧洲多学科肿瘤委员会越来越支持罕见妇科肿瘤患者的管理：6年活动结果
European multi-disciplinary tumor boards within the EURACAN network increasingly support management of patients with rare gynaecological tumors: 6 year activity results.
讲者：Alice Bergamini (Milan, Italy)
摘要号：45MO
I期卵巢Sertoli-Leydig细胞瘤的治疗管理：一项国际多中心回顾性研究的预后因素
Management of stage I ovarian Sertoli-Leydig cell tumors: prognostic factors from a multicenter international retrospective study.
讲者：Giovanna Scarfone (Milano, Italy)
迷你口头报告专场2
Mini Oral session 2
专场时间：2024.06.21 16:30 - 17:45
专场主席：Philipp Harter (Essen, Germany)；Kosei Hasegawa (Saitama, Japan)
摘要号：46MO
晚期卵巢癌患者间隔减瘤手术 (CC0-IDS) 成功的预测因素是什么？来自两个大型独立数据集的一致数据
What are the predictors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers? Consistent data from two large independent datasets
讲者：Adriana Ionelia Apostol (Rome, Italy)
摘要号：47MO
MITO-MANGO-ENGOT研究：MiROvaR（一种基于miRNA的分类器）定义的早期复发风险指数，可能是贝伐珠单抗疗效的潜在预测标志物
The risk index of early relapse defined by MiROvaR, a miRNA-based classifier, is a potential predictive marker for bevacizumab benefit: a MITO-MANGO-ENGOT study
讲者：Marina Bagnoli (Milan, Italy)
摘要号：48MO
德国老年晚期卵巢癌患者的治疗和结局-AGO研究组的QS Ovar
Treatment and outcome of elderly patients with advanced ovarian cancer in Germany - QS Ovar of the AGO Study Group
讲者：Felix Hilpert (Hamburg, Germany)
摘要号：49MO
ATHENA-MONO：接受rucaparib治疗的新诊断晚期卵巢癌患者的更新无进展生存期
Updated progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) treated with rucaparib (RUC) in ATHENA-MONO
讲者：Rebecca Kristeleit (London, United Kingdom)
摘要号：41MO
未治疗子宫内膜癌中的ESR1突变：来自UTOLA试验的流行病学、特征和预后意义
ESR1 mutation in Untreated Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications from the UTOLA Trial
讲者：Felix Blanc-Durand (Villejuif, Cedex, France)
摘要号：42MO
从全面基因组分析中解释子宫内膜癌的体细胞 POLE 突变
Interpreting somatic POLE mutations in endometrial cancer emerging from comprehensive genomic profiling
讲者：Rita Trozzi (Rome, Italy)
摘要号：24MO
TROP-2、TF和NECTIN4 作为宫颈癌 ADC 治疗的靶点
TROP-2, TF and NECTIN4 as targets for ADC treatment in cervical cancer
讲者：Mari Halle (Bergen, Norway)
会议日程
https://cslide.ctimeetingtech.com/gynae24hybrid/attendee/confcal/session/calendar
排版编辑：肿瘤资讯-张薪媛
苏公网安备32059002004080号
